$ cat ./records/committed-40-million-to-advance-mrna-vaccine-manufacturing-in-afr-2023.txt
Committed $40 million to advance mRNA vaccine manufacturing in Africa and globally
[RECORD.TXT] · cat --full
At the Grand Challenges Annual Meeting in Accra, Gates announced $40 million in new investments to advance access to mRNA research and vaccine manufacturing technology in low- and middle-income countries. Key recipients included Quantoom Biosciences, which received funding to deploy a low-cost mRNA manufacturing platform, and the Institut Pasteur de Dakar and Biovac in South Africa, each receiving $5 million to acquire the technology. The initiative extended the COVID-19 mRNA revolution to the neglected diseases — tuberculosis, malaria, and Lassa fever — that disproportionately burden the developing world.
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
Backed Breakthrough Energy startup using liquid tin to store solar and wind energy as industrial heat
Next →
Malaria deaths reduced by more than 60% since 2000 through Gates-backed programs
[CROSS_REFERENCES] · grep --category='Global Health'
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
2025
Gates-Funded Monoclonal Antibody Shows Early Promise as a Single-Shot Malaria Shield
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.